

Factsheet | The Biosimilar Medicines Group



About the Biosimilar Medicines Group


The **Biosimilar Medicines Group**, a sector group of **Medicines for Europe**, represents the leading companies in the biosimilar medicines space. The Biosimilar Medicines Group members bring competition to the biologicals market, thereby increasing access to highly innovative medical treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

Medicines for Europe represents the European generic, biosimilar and value added medicines industries, which provide high-quality cost-competitive medicines to millions of Europeans. The vision of **Medicines for Europe** is to provide sustainable access to high quality medicines for all European patients, based on 5 important pillars: **patients, quality, value, sustainability** and **partnership**.

The Biosimilar Medicines Group is open to **Medicines for Europe** and non-**Medicines for Europe** members.

For more information please follow us at www.medicinesforeurope.com and on Twitter [@biosimilarsEU](https://twitter.com/biosimilarsEU)

Biosimilar Medicines: Key Facts



Biosimilar Medicines Group Membership

COMPANIES

Accord Healthcare
Allergan
Baxalta
Boehringer Ingelheim
Cinfa Biotech
Egis
Gedeon Richter

Merck Serono
Mylan
Polpharma
Sandoz
Stada
Teva

NATIONAL ASSOCIATIONS

AESEG (Spain)
APOGEN (Portugal)
AssoGenerici (Italy)
BGMA (United Kingdom)
BOGIN (Netherlands)
CAFF (Czech Republic)
FeBelGen (Belgium)

FGL (Sweden)
GEMME (France)
IEIS (Turkey)
IGL (Denmark)
Intergenerika (Switzerland)
Progenerika (Germany)



Follow us on

